Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA

Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q1 2013 Earnings Presentation

18 slides from Sun Pharmaceutical Industries's earnings presentation, May 8, 2013

  1. Slide 1: Financial Results: January – March 2013 (Q1 2013)

    FINANCIAL RESULTS: January – March 2013 (Q1 2013) ARUN SAWHNEY CEO & MD Dept. 08 May Name 2013 Post Results Conference Call Privileged and Confidential

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p

  3. Slide 3: Highlights: Quarter 1, 2013 (Financial)

    1/2 Highlights: Quarter 1, 2013 Financial  Base business sales grew by >10% over the corresponding quarter  EBITDA margins on base business continue to improve 37,090 29% 24,398 Percent Rs. Mn 6% Q1 2012 Q1 2013 Q1 2012 Q1 2013 Sales EBITDA/ Sales% Growth calculated on Constant Forex Privileged an

  4. Slide 4: Highlights: Quarter 1, 2013 (Business)

    2/2 Highlights: Quarter 1, 2013 In-licensing agreement for Desvenlafaxine in Business USA  Branded and OTC category sales Rs.12,238 Mn  50% of sales for the Quarter  Generic including API category sales Rs. 12,160 Mn  USA:  India:  Strong base business sales  Performance in represented segmen

  5. Slide 5: Functional Performance

    Functional Performance Manufacturing  Supplies of Atorvastatin resumed for the USA market Research & Development  Regulatory Filings and approvals  DF filings: 43; DF approvals: 22  3 ANDAs filed in USA (2 potential FTFs) Growth calculated on Constant Forex Privileged and Confidential 5

  6. Slide 6: Hybrid Business Model

    Hybrid Business Model Synergy with Daiichi Sankyo  Front end:  Ranbaxy and DS launch Hybrid Business in Brazil to expand business of both Companies  Ongoing:  R&D collaborations continue to address various markets and cost efficiencies Growth calculated on Constant Forex Privileged and Confident

  7. Slide 7: Other Areas

    Other Areas Regulatory  Consent Decree: satisfactory progress Derivatives Position  Exposure down to ~$962 Mn as on 31 Mar 2013 from ~1.07 Bn in Q4 2012. Maturity: ~$36 Mn/Month Debt  Total Debt $824 Mn; Cash & Bank Bal $658 Mn  Net Debt $167 Mn Growth calculated on Constant Forex Privileged and

  8. Slide 8: Financial Performance

    Financial Performance FINANCIAL RESULTS: January – Mar 2013 (Q1) Dept. 08 May Name 2013 Post Results Conference Call Privileged and Confidential

  9. Slide 9: Sales Performance

    Sales Performance Rs. Mn Consolidated Sales Q1 2013 37,090 24,398 (37%) Q1 2012 Q1 2013  Base business sales grew by >10% over the corresponding quarter  Sales grew across key emerging markets during the Quarter Growth calculated on Constant Forex Privileged and Confidential 9

  10. Slide 10: North America

    North America Rs. Mn Major markets -USA -Canada 20,929 6,892 (69%) Q1 2012 Q1 2013  Sales in the USA impacted due to absence of large exclusivity sales compared to the corresponding quarter  Encouraging prescription trend in Absorica™ Growth calculated on Constant Forex Privileged and Confidential

  11. Slide 11: India

    India Rs. Mn 5,427 4,887 11% Q1 2012 Q1 2013  Sales growth better than the IPM  Continued strong performance in the OTC part of the business Growth calculated on Constant Forex Privileged and Confidential 11

  12. Slide 12: East Europe & CIS

    East Europe & CIS Rs. Mn Major markets -Romania -Russia -Ukraine 3,604 2,922 15% Q1 2012 Q1 2013  Overall strong sales performance  Maintained leadership position in Romania and Russia Growth calculated on Constant Forex Privileged and Confidential 12

  13. Slide 13: West Europe

    West Europe Rs. Mn Major markets -France -Germany -UK 2,284 2,018 (18%) Q1 2012 Q1 2013  Market conditions continued to impact business performance Growth calculated on Constant Forex Privileged and Confidential 13

  14. Slide 14: Asia Pacific & Latin America

    Asia Pacific & Latin America Rs. Mn Major markets -ANZ -Malaysia -Brazil 1,951 1,659 (19%) Q1 2012 Q1 2013  New business region  Sales in Australia impacted by absence of Atorvastatin during the Quarter Growth calculated on Constant Forex Privileged and Confidential 14

  15. Slide 15: Africa & Middle East

    Africa & Middle East Rs. Mn Major markets -South Africa -Nigeria 2,983 2,438 23% Q1 2012 Q1 2013  Strong sales performance due to contribution from the Sonke plant  Plan to strengthen infrastructure, specifically in Nigeria and Egypt Growth calculated on Constant Forex Privileged and Confidential

  16. Slide 16: API & Others

    API & Others Rs. Mn 1,815 1,678 1% Q1 2012 Q1 2013  Continued focus on profitability Growth calculated on Constant Forex Privileged and Confidential 16

  17. Slide 17: Financials Q1 2013 INR Mn

    Financials Q1 2013 INR Mn Q1'12 Particulars Q1’13 5,037 - Within India 5,611 32,053 - Outside India 18,787 37,090 Sales 24,398 723 Other operating income 607 37,813 Total Operating Income 25,006 8,445 Total Material Consumption 8,979 4,739 Employee cost 4,862 6,948 Claims and contractual payments 23

  18. Slide 18: Questions & Answers

    Questions & Answers Dept. Name Privileged and Confidential

Ranbaxy Laboratories — Q1 2013 Earnings Presentation on 6ix